JavaScript is required for full functionality of this website. Please follow these simple instructions to enable JavaScript in your web browser. Please refresh this page once you have done so.

If you are still seeing this message after enabling JavaScript, please contact for further assistance.
Warning: you are accessing this website using an insecure browser. Since January 12, 2016, only the most current version of Internet Explorer available for a supported operating system receives technical support and security updates:

Our website accepts credit card payments. This requires a modern internet browser. We want to provide the best security for you and other user's financial information. On this basis, you may only access this website with the latest supported version of Internet Explorer or Microsoft Edge. Please see the most recent versions here:

As an alternative, we highly recommend using either Google Chrome or Mozilla Firefox. Both of these browsers are well known for always maintaining the highest security features.

If you are still seeing this message after installing and using one of the above browsers, please contact for further assistance.
Error: you must enable TLS 1.2 encryption to make a payment.
  1. Click the settings (Tools) icon in the top right corner.
  2. Select Internet Options
  3. Go to the Advanced tab
  4. Scroll down to the Security section
  5. Uncheck SSL 2.0 and SSL 3.0
  6. Check TLS 1.2
  7. Refresh the page
Enable TLS 1.2

If you are still seeing this message after enabling TLS 1.2, please contact for further assistance.
Public and Regulatory Policy
Join the Public and Regulatory Policy

Public and Regulatory Policy Committee

Chair:  Erin Davis

Chair-elect: TBD

video about this committee



Our mission is to advocate on behalf of ICCAC by influencing international, regional, and state public policies relating to mechanical circulatory support. As a committee, we monitor legislation and regulatory agencies as they relate to MCS. These include but are not limited to, NIH, FDA, CMS, the Joint Commission, DNV, UNOS, and other international or regional regulatory bodies. Our vision is to review upcoming regulatory changes, inform our members about open comment periods, and create relevant society-level responses, approved by the ICCAC Board of Directors, to be delivered to appropriate regulatory bodies.

2022 Goals

Have 1st meeting End of Aug 2022 to review and confirm these bylaws and determine deliverables for the next 2 quarters

Review which regulatory bodies will be followed closely by this committee and confirm with Executive Board


Joint Commission


CDC / Coding Clinic



NIH & other European Regulatory Bodies as applicable

Other International Regulatory Bodies

Chair and Committee Member Requirements

  • At least 3 members are recommended to maintain the efficiency of the committee. There is no maximum number of members.
  • Recommend at least 1 international member, but not a requirement. Any International ICCAC member is invited to join committee calls to bring to attention international policies or regulations relating to MCS therapy
  • Recruitment is achieved through current ICCAC membership, MCS collaboration board, emails, social media, and word of mouth via colleagues
  • Chair of the committee is strictly voluntary and the individual who volunteers shall remain in the chair position for a minimum of 1 year
  • If there are no other volunteers to follow the Chair position, the individual in the chair position can maintain in this role until another volunteer is found
  • Co-Chair (if established) will take over January of the following year and will change to “Chair” status at to which time active recruitment for future co-chairs will take place
  • Minimum 1 year as MCS clinician
  • Active ICCAC Member
  • Active committee members must participate in >50% of meeting phone calls. Should schedule conflicts occur, an email including project updates will suffice.
  • Industry ICCAC members may fully participate in the committee, but may not hold the Chair or Co-Chair position

Scope and Objectives

  • Monitor legislation and regulations involving MCS therapies and report to ICCAC Board Quarterly. These include, but are not limited to, NIH, FDA, CMS, the Joint Commission, DNV, UNOS, and other international or regional regulatory bodies that the committee is made aware of by International ICCAC members.
  • Inform ICCAC membership of upcoming policy and regulation changes relating to MCS therapy
  • Create society-level responses to open public comment periods for MCS therapy–related policy or regulation changes

Committee Chairs
Erin Davis

If you have any questions, please contact